Drug Supply Chain Security Act of 2013 and Its Computer System Implementation

Drug Supply Chain Security Act of 2013 and Its Computer System Implementation

Author: Daryl O. Jones

Publisher:

Published: 2014

Total Pages: 240

ISBN-13:

DOWNLOAD EBOOK

"Since 1987, the federal government and later, the state governments, have tried to combat counterfeit drugs from entering the United States and the state's pharmaceutical supply chain. The latest attempt to prevent counterfeit drugs from entering the state drug supply chain was the California E-Pedigree drug tracing program that was to be implemented by the end of 2017. The California E-Pedigree system uses GS1 PDMS tracing system as its guideline. Since all of the states use paper format pedigree systems, California would have been the first electronic pedigree system in the U.S. However, on November 27, 2013, the President of the United States signed into law the Drug Quality Security Act (DQSA). Title II of DQSA is called Drug Supply Chain Security Act (DSCSA) and it removes all existing or future drug track or trace systems including pedigree systems from all states. DSCSA does establish a new federal drug tracing program that uses pedigrees and product identifiers for verification of the drugs being accepted by the buyer. Although the full implementation of the DSCSA will take about ten years from its enactment, the basic structure of the new federal tracing program is laid out. My thesis will analyze the current state of the pharmaceutical industry, the impact from counterfeit medicine, and anti-counterfeit technologies. We will proceed to analyze the DSCSA to create a basic logical model and show a possible implementation of its verification process. Additionally, we will discuss DSCSA model as to its effectiveness of the basic design against the entrance of counterfeit medicine into the United States Pharmaceutical Supply Chain. This will be followed by a conclusion"--Leaf iv.


The Drug Supply Chain Security Act Explained

The Drug Supply Chain Security Act Explained

Author: Dirk Rodgers

Publisher: Createspace Independent Publishing Platform

Published: 2016-01-26

Total Pages: 352

ISBN-13: 9781522904908

DOWNLOAD EBOOK

The Drug Supply Chain Security Act (DSCSA) was passed by Congress in the fall of 2013 and signed into law by President Barack Obama on November 27, 2013. The DSCSA was Title II of the Drug Quality and Security Act (DQSA). The law establishes new requirements that must be administered by the Food and Drug Administration (FDA). These requirements escalate over time from 2015 through 2023 in a series of stages. They include lot-based tracing of prescription pharmaceuticals from the manufacturer to the dispenser from 2015 through 2023 and serialization-based tracing after 2023. Drug manufacturers must apply unique identifiers on all prescription drug packages by November 2017 and repackagers, wholesale distributors and dispensers must begin to buy and sell products marked with those identifiers by November of 2018, 2019 and 2020 respectively. This book explains the DSCSA, section by section, so that drug manufacturers, repackagers, wholesale distributors, dispensers, contract partners (CMOs, CPOs, 3PLs), solution providers, consultants, law firms, regulators and students can understand the text, the meaning and the significance of the law. The book also includes more than two dozen of the most informative RxTrace essays about various aspects of the DSCSA. These essays, by Dirk Rodgers, help to expose the implications of the law and provide the context necessary to understand its full impact on companies in the supply chain. In these essays, the latest FDA guidance related to the DSCSA, as of book publication, are explained. Praise for The Drug Supply Chain Security Act Explained, Second Edition: "Dirk Rodgers has an unparalleled knowledge of federal track and trace legislation. This book is essential reading for anyone who wants to understand and benefit from coming changes to the pharmaceutical supply chain." -- Adam J. Fein, Ph.D., president, Pembroke Consulting, Inc., and CEO, Drug Channels Institute "Through RxTrace, Dirk Rodgers has provided stakeholders valuable insights on DSCSA. As DSCSA has evolved, his questions and opinions have helped all the stakeholders understand compliance. Dirk's new book brings years of wisdom from RxTrace and more together in one volume." -- Napoleon Monroe, Managing Director, New Directions Technology Consulting, LLC "As dispensers entrusted with the last encounter for patient safety, it is important to have a venue for discussion on DSCSA implementation challenges amongst trading partners. In this book, Dirk provides his experience as a resource for companies to use to create solutions." -- Chris Chandler, PharmD, VP of USDM Healthcare


Good Design Practices for GMP Pharmaceutical Facilities

Good Design Practices for GMP Pharmaceutical Facilities

Author: Terry Jacobs

Publisher: CRC Press

Published: 2016-08-19

Total Pages: 674

ISBN-13: 1315355027

DOWNLOAD EBOOK

This revised publication serves as a handy and current reference for professionals engaged in planning, designing, building, validating and maintaining modern cGMP pharmaceutical manufacturing facilities in the U.S. and internationally. The new edition expands on facility planning, with a focus on the ever-growing need to modify existing legacy facilities, and on current trends in pharmaceutical manufacturing which include strategies for sustainability and LEED building ratings. All chapters have been re-examined with a fresh outlook on current good design practices.


Introduction to Acute and Ambulatory Care Pharmacy Practice

Introduction to Acute and Ambulatory Care Pharmacy Practice

Author: David A. Holdford

Publisher: ASHP

Published: 2017-06-30

Total Pages: 481

ISBN-13: 1585285471

DOWNLOAD EBOOK

Learn How to Thrive in Today’s Institutional Pharmacy Practice Landscape With ASHP’s Introduction to Acute and Ambulatory Care Pharmacy Practice, Second Edition, pharmacy students and technicians can gain a professional head start by learning essential vocabulary, legal and regulatory issues, and the core clinical and administrative pharmacy operations in various practice settings. It is also a useful reference for new practitioners and anyone else interested in institutional pharmacy’s current financial, technological, and distributional systems. Written by David A. Holdford, RPh, MS, PhD, FAPhA, with additional content from 27 leading experts, the second edition provides a thorough introduction to all aspects of the institutional pharmacy practice in both hospital and outpatient settings, with a special focus on the developing role of technicians. It has been thoroughly updated to cover all current developments, and is clearly written, with Key Facts, What Ifs, and other learning enhancements that make terms, concepts, and processes easy to understand and apply. The Only Comprehensive Introductory Guide, Updated and Expanded Two new and 18 updated chapters cover topics, including: Key legal and regulatory issues Managing medication use and distribution Professional terminology Technology and automation Financial management, inventory, and cost control Sterile product preparation and administration Managing people and leadership Careers and training options The expanding role of pharmacy technicians Along with an understanding of the workings of institutional practice, students and new pharmacists can acquire the terminology that enables them to speak knowledgeably, along with insight into professional opportunities, including some non-traditional ones.


Countering the Problem of Falsified and Substandard Drugs

Countering the Problem of Falsified and Substandard Drugs

Author: Institute of Medicine

Publisher: National Academies Press

Published: 2013-06-20

Total Pages: 377

ISBN-13: 0309269393

DOWNLOAD EBOOK

The adulteration and fraudulent manufacture of medicines is an old problem, vastly aggravated by modern manufacturing and trade. In the last decade, impotent antimicrobial drugs have compromised the treatment of many deadly diseases in poor countries. More recently, negligent production at a Massachusetts compounding pharmacy sickened hundreds of Americans. While the national drugs regulatory authority (hereafter, the regulatory authority) is responsible for the safety of a country's drug supply, no single country can entirely guarantee this today. The once common use of the term counterfeit to describe any drug that is not what it claims to be is at the heart of the argument. In a narrow, legal sense a counterfeit drug is one that infringes on a registered trademark. The lay meaning is much broader, including any drug made with intentional deceit. Some generic drug companies and civil society groups object to calling bad medicines counterfeit, seeing it as the deliberate conflation of public health and intellectual property concerns. Countering the Problem of Falsified and Substandard Drugs accepts the narrow meaning of counterfeit, and, because the nuances of trademark infringement must be dealt with by courts, case by case, the report does not discuss the problem of counterfeit medicines.


Enterprise Level Security 1 & 2

Enterprise Level Security 1 & 2

Author: Kevin Foltz

Publisher: CRC Press

Published: 2022-05-29

Total Pages: 752

ISBN-13: 1000165175

DOWNLOAD EBOOK

This set comprises of Enterprise Level Security and Enterprise Level Security 2. ELS provides a modern alternative to the fortress approach to security. ELS 2 follows on from the first book, which covered the basic concepts of ELS, to give a discussion of advanced topics and solutions.


Enterprise Level Security 2

Enterprise Level Security 2

Author: Kevin E. Foltz

Publisher: CRC Press

Published: 2020-09-14

Total Pages: 314

ISBN-13: 1000165167

DOWNLOAD EBOOK

Enterprise Level Security 2: Advanced Topics in an Uncertain World follows on from the authors’ first book on Enterprise Level Security (ELS), which covered the basic concepts of ELS and the discoveries made during the first eight years of its development. This book follows on from this to give a discussion of advanced topics and solutions, derived from 16 years of research, pilots, and operational trials in putting an enterprise system together. The chapters cover specific advanced topics derived from painful mistakes and numerous revisions of processes. This book covers many of the topics omitted from the first book including multi-factor authentication, cloud key management, enterprise change management, entity veracity, homomorphic computing, device management, mobile ad hoc, big data, mediation, and several other topics. The ELS model of enterprise security is endorsed by the Secretary of the Air Force for Air Force computing systems and is a candidate for DoD systems under the Joint Information Environment Program. The book is intended for enterprise IT architecture developers, application developers, and IT security professionals. This is a unique approach to end-to-end security and fills a niche in the market.


Developing Solid Oral Dosage Forms

Developing Solid Oral Dosage Forms

Author: Yihong Qiu

Publisher: Academic Press

Published: 2016-11-08

Total Pages: 1178

ISBN-13: 0128026375

DOWNLOAD EBOOK

Developing Solid Oral Dosage Forms: Pharmaceutical Theory and Practice, Second Edition illustrates how to develop high-quality, safe, and effective pharmaceutical products by discussing the latest techniques, tools, and scientific advances in preformulation investigation, formulation, process design, characterization, scale-up, and production operations. This book covers the essential principles of physical pharmacy, biopharmaceutics, and industrial pharmacy, and their application to the research and development process of oral dosage forms. Chapters have been added, combined, deleted, and completely revised as necessary to produce a comprehensive, well-organized, valuable reference for industry professionals and academics engaged in all aspects of the development process. New and important topics include spray drying, amorphous solid dispersion using hot-melt extrusion, modeling and simulation, bioequivalence of complex modified-released dosage forms, biowaivers, and much more. - Written and edited by an international team of leading experts with experience and knowledge across industry, academia, and regulatory settings - Includes new chapters covering the pharmaceutical applications of surface phenomenon, predictive biopharmaceutics and pharmacokinetics, the development of formulations for drug discovery support, and much more - Presents new case studies throughout, and a section completely devoted to regulatory aspects, including global product regulation and international perspectives